

# PHARMACEUTICAL PATENT LAW

Third Edition

**John R. Thomas**

*Professor of Law  
Georgetown University Law Center  
Washington, DC*

**Bloomberg  
BNA**

Bloomberg BNA, Arlington, VA

# Detailed Table of Contents

|                                 |      |
|---------------------------------|------|
| Foreword.....                   | vii  |
| Preface .....                   | xi   |
| Summary Table of Contents ..... | xiii |

## I. Introduction

|  |    |
|--|----|
| 1. Introduction to Pharmaceutical Patents.....   | 3  |
| I. The Drug Patent Debate.....   | 4  |
| II. Overview of the Patent Law .....   | 5  |
| III. Overview of the Marketing Approval Process .....                                  | 7  |
| IV. A Brief History of Pharmaceutical Patent Law and<br>Food and Drug Law .....        | 9  |
| A. <i>Roche v. Bolar</i> .....   | 10 |
| B. The Hatch-Waxman Act.....   | 13 |
| 1. The Statutory Experimental Use Exception.....                                       | 14 |
| 2. Abbreviated New Drug Applications.....  | 14 |
| 3. Certifications for Orange Book-Listed Patents....                                   | 15 |
| 4. Patent Infringement Proceedings.....  | 17 |
| 5. Patent Term Extension.....  | 18 |
| 6. Regulatory Exclusivities .....  | 19 |
| 7. Generic Exclusivity .....   | 20 |
| 8. The Impact of the Hatch-Waxman Act.....   | 20 |
| C. The Generic Animal Drug and Patent<br>Term Restoration Act .....                    | 20 |
| D. The Uruguay Round Agreements Act of 1995.....                                       | 21 |
| E. The FDA Modernization Act.....  | 21 |
| F. The American Inventors Protection Act of 1999.....                                  | 22 |
| G. The 2003 FDA Regulations.....   | 22 |
| H. The Medicare Prescription Drug, Improvement, and<br>Modernization Act of 2003 ..... | 23 |
| 1. Single 30-Month Stay.....   | 23 |
| 2. Notice of Applications.....   | 23 |
| 3. Counterclaim for Patent De-Listing.....   | 24 |

|  |    |
|--|----|
| 4. Declaratory Judgment Actions .....                            | 24 |
| 5. Generic Exclusivity .....                                     | 24 |
| 6. Notice of Agreements .....                                    | 25 |
| I. The Food and Drug Administration Amendments Act of 2007 ..... | 25 |
| J. The QI Program and Supplemental Funding Act of 2008 .....     | 25 |
| K. The Biologics Price Competition and Innovation Act .....      | 26 |
| L. The Leahy-Smith America Invents Act .....                     | 27 |
| M. The GAIN Act .....  | 28 |
| N. Ongoing Legislative Reform Efforts .....                      | 28 |

## II. Patent Acquisition

|  |    |
|--|----|
| 2. Patent Eligibility .....  | 33 |
| I. Basic Concepts .....  | 33 |
| II. Product and Process Claims .....                                 | 34 |
| A. Abstract Ideas .....  | 35 |
| B. Products of Nature .....  | 37 |
| C. Living Inventions .....   | 43 |
| D. Process Claims for New Uses .....                                 | 46 |
| III. Types of Pharmaceutical Patent Claims .....                     | 46 |
| A. Drug Substances .....   | 47 |
| B. Formulations .....  | 47 |
| C. Chemical Intermediates .....                                      | 48 |
| D. Metabolites and Prodrugs .....                                    | 48 |
| E. Crystals and Polymorphs .....                                     | 50 |
| F. Isomers .....   | 51 |
| G. Salts .....   | 52 |
| H. Combination Therapies .....                                       | 53 |
| I. Methods of Using .....  | 53 |
| J. Methods of Making .....   | 54 |
| K. Methods of Diagnosis .....  | 55 |
| L. Kits .....  | 60 |
| IV. Methods of Medical Treatment .....                               | 61 |
| 3. Utility .....   | 65 |
| I. Introduction .....  | 65 |
| II. Moral Utility .....  | 68 |
| III. Practical Utility .....   | 72 |
| IV. Practical Utility for Pharmaceutical Patents .....               | 75 |
| A. <i>Brenner v. Manson</i> .....                                    | 76 |
| B. Leading Case Law of the Court of Customs and Patent Appeals ..... | 79 |
| C. Early Case Law of the Federal Circuit .....                       | 80 |
| D. The 1995 PTO Utility Examination Guidelines .....                 | 82 |

|  |     |
|--|-----|
| E. The 2001 PTO Utility Examination Guidelines .....                       | 84  |
| F. <i>In re Fisher</i> .....   | 85  |
| V. Recurring Issues.....   | 89  |
| A. Safety and Efficacy Considerations.....                                 | 89  |
| B. Structural Similarity to Compounds With an<br>Established Utility ..... | 93  |
| C. <i>In Vitro</i> and <i>In Vivo</i> Tests .....                          | 94  |
| D. Human Clinical Data .....   | 97  |
| E. Chemical Intermediates.....   | 98  |
| F. Inoperable Species Within a Genus.....                                  | 99  |
| G. Assertions of Multiple Utilities .....                                  | 100 |
| H. The Utility Requirement in Adversarial<br>Proceedings.....              | 101 |
| I. The Utility Requirement and Priority Applications..                     | 103 |
| 4. Novelty.....  | 107 |
| I. Introduction.....   | 108 |
| II. Anticipation .....   | 111 |
| A. Genus and Species.....  | 112 |
| B. The Enablement Requirement .....  | 118 |
| III. Inherency.....  | 121 |
| IV. Novelty Under the AIA .....  | 136 |
| A. "Public Use" .....  | 137 |
| B. "On Sale" .....   | 143 |
| C. Patents .....   | 147 |
| D. Printed Publications.....   | 148 |
| E. "Otherwise Available to the Public" .....                               | 149 |
| F. Experimental Use.....   | 150 |
| G. Disclosure in U.S. Patent Applications .....                            | 153 |
| V. Novelty Pre-AIA .....   | 155 |
| A. Pre-AIA Statutory Bars .....  | 155 |
| B. Prior Invention Under 35 U.S.C. §102(a) .....                           | 157 |
| C. Prior Invention Under 35 U.S.C. §102(g) .....                           | 160 |
| 1. Prior Art Under 35 U.S.C. §102(g) .....                                 | 161 |
| 2. Priority Under 35 U.S.C. §102(g) .....                                  | 162 |
| 3. Inventive Activity in Foreign Countries.....                            | 162 |
| 4. Conception .....  | 163 |
| 5. Reduction to Practice .....   | 166 |
| 6. Diligence .....   | 168 |
| 7. Corroboration.....  | 170 |
| 8. Patent Award to the Second Inventor .....                               | 173 |
| D. Disclosure in U.S. Patent Applications.....                             | 177 |
| E. Derivation .....  | 177 |
| 5. Nonobviousness.....   | 179 |
| I. Introduction.....   | 180 |
| II. Fundamentals of the Nonobviousness Inquiry.....                        | 180 |
| A. The Historical Standard of Invention .....                              | 181 |

|  |     |
|--|-----|
| B. The Patent Act of 1952 .....                              | 182 |
| C. <i>KSR v. Teleflex</i> .....                              | 187 |
| D. The Person of Ordinary Skill in the Art .....             | 191 |
| E. The Prima Facie Case of Obviousness .....                 | 194 |
| F. Obvious to Try .....                                      | 196 |
| G. Analogous Arts .....                                      | 198 |
| H. Nonfunctional Additions .....                             | 199 |
| III. The Secondary Considerations .....                      | 201 |
| A. Commercial Success .....                                  | 203 |
| B. Copying .....   | 207 |
| C. Licenses .....  | 208 |
| D. Prior Failures of Others .....                            | 209 |
| E. Long-Felt Need .....                                      | 211 |
| F. Praise and Skepticism .....                               | 212 |
| G. Unexpected Results .....                                  | 213 |
| IV. Structural Similarities as Evidence of Obviousness ..... | 216 |
| A. Introduction .....  | 216 |
| B. Lead Compound Analysis .....                              | 222 |
| C. Examples of Structural Relationships .....                | 226 |
| D. Homologues .....  | 228 |
| 1. Adjacent Homologues .....                                 | 228 |
| 2. Ring Expansion and Contraction .....                      | 230 |
| 3. Remote Homologues .....                                   | 232 |
| E. Isomers .....   | 233 |
| 1. Structural Isomerism .....                                | 233 |
| a. Position Isomerism .....                                  | 234 |
| b. Tautomers .....   | 235 |
| c. Stereoisomers .....                                       | 236 |
| 2. Bioisomerism .....  | 244 |
| F. Esters .....  | 245 |
| 1. Prior Art Alcohols .....                                  | 245 |
| 2. Prior Art Free Acids .....                                | 247 |
| G. Analogs .....   | 247 |
| 6. The Patent Instrument .....                               | 249 |
| I. Enablement .....  | 251 |
| A. Basic Concepts .....                                      | 251 |
| B. Working and Prophetic Examples .....                      | 260 |
| C. Exhibits and Biological Samples .....                     | 261 |
| II. Best Mode .....  | 262 |
| III. Written Description .....                               | 267 |
| A. New Matter .....  | 267 |
| B. Originally Filed Claims .....                             | 271 |
| IV. The Claims .....   | 274 |
| A. Basic Claim Drafting .....                                | 275 |
| 1. The Preamble .....  | 275 |
| 2. The Transition Phrase .....                               | 278 |

|  |     |
|--|-----|
| 3. The Body .....  | 281 |
| B. Claim Formats .....   | 282 |
| 1. Dependent Claims .....  | 282 |
| 2. Markush Claims .....  | 284 |
| 3. Product-by-Process Claims .....                                   | 285 |
| 4. Jepson Claims .....   | 288 |
| 5. Functional Claims .....   | 289 |
| 6. Skuballa Claims .....   | 293 |
| 7. First Medical Use and Swiss-Style Claims .....                    | 294 |
| C. Definiteness .....  | 295 |
| 7. Patent Acquisition Procedures .....                               | 301 |
| I. Fundamentals of Patent Prosecution .....                          | 302 |
| A. Preparation of Applications .....                                 | 302 |
| B. Provisional Applications .....                                    | 304 |
| C. Examination of Applications .....                                 | 305 |
| D. Continuing Applications .....                                     | 307 |
| E. The Restriction Requirement and<br>Divisional Applications .....  | 308 |
| F. Publication of Applications .....                                 | 309 |
| G. Petition and Appeal .....   | 311 |
| H. Invention Secrecy Orders .....                                    | 312 |
| II. Other PTO Proceedings .....                                      | 312 |
| A. Protests .....  | 312 |
| B. Pre-Issuance Submissions .....                                    | 313 |
| C. Citation of Prior Art .....                                       | 314 |
| D. Public Use Proceedings .....                                      | 314 |
| III. Post-Grant Proceedings .....                                    | 315 |
| A. Certificates of Correction .....                                  | 315 |
| B. Disclaimers .....   | 316 |
| C. Reissue .....   | 316 |
| D. Ex parte Reexamination .....                                      | 319 |
| E. Post-Grant Review and Inter Partes Review .....                   | 321 |
| F. Intervening Rights .....  | 322 |
| G. Supplemental Examination .....                                    | 324 |
| H. Transitional Program for Covered Business Method<br>Patents ..... | 324 |
| IV. Abuses of Patent Acquisition Procedures .....                    | 325 |
| A. Double Patenting .....  | 325 |
| 1. Basic Principles .....  | 325 |
| 2. Double Patenting and the Restriction<br>Requirement .....         | 333 |
| 3. Two-Way Double Patenting .....                                    | 335 |
| B. Inequitable Conduct .....   | 336 |
| C. Misjoinder or Nonjoinder of Inventors .....                       | 343 |
| D. Prosecution Laches .....  | 345 |

|  |     |
|--|-----|
| 8. Duration of Rights.....                       | 349 |
| I. Fundamentals of Patent Term.....              | 350 |
| II. Maintenance Fees.....                        | 351 |
| III. The Patent Term Guarantee Act .....         | 351 |
| IV. Specialized Legislation .....                | 352 |
| V. The Hatch-Waxman Act.....                     | 352 |
| A. Eligible Patents .....                        | 353 |
| 1. Drug Products.....                            | 353 |
| 2. Combination Therapies.....                    | 358 |
| 3. Metabolites .....                             | 360 |
| 4. Stereoisomers .....                           | 361 |
| 5. Medical Devices .....                         | 361 |
| 6. Patents Subject to a Terminal Disclaimer..... | 363 |
| B. Application for Term Extension.....           | 365 |
| 1. Time Limit for Filing.....                    | 365 |
| 2. Identity of the Applicant .....               | 367 |
| 3. Contents.....                                 | 367 |
| 4. Review of the Application.....                | 368 |
| 5. Interim Extensions.....                       | 369 |
| 6. Strategic Considerations.....                 | 370 |
| C. Period of Extension .....                     | 370 |
| D. Limitation Upon Scope of Rights.....          | 372 |

### **III. Marketing Approval Procedures**

|  |     |
|--|-----|
| 9. The FDA Drug Approval Process .....                         | 377 |
| I. Marketing Approval for Innovative Drugs .....               | 378 |
| A. Preclinical Investigations .....                            | 378 |
| B. Investigational New Drug Applications.....                  | 379 |
| 1. Phase I Investigations.....                                 | 380 |
| 2. Phase II Investigations .....                               | 380 |
| 3. Phase III Investigations.....                               | 380 |
| 4. Emergency INDs .....  | 381 |
| 5. Screening INDs.....   | 381 |
| C. New Drug Applications .....                                 | 381 |
| D. Supplemental New Drug Applications.....                     | 382 |
| E. Postmarketing Surveillance/Phase IV<br>Investigations ..... | 383 |
| II. Marketing Approval for Generic Drugs .....                 | 383 |
| A. FDA Practices Prior to Hatch-Waxman .....                   | 384 |
| B. Abbreviated New Drug Applications.....                      | 385 |
| C. Section 505(b)(2) Applications .....                        | 387 |
| D. Patent Certifications .....                                 | 389 |
| E. Section viii Statements .....                               | 390 |
| F. Thirty-Month Stay of Marketing Approval.....                | 396 |
| 1. Multiple 30-Month Stays .....                               | 399 |
| 2. Judicial Modification of the 30-Month Period.....           | 402 |

|  |     |
|--|-----|
| III. Antibiotics.....  | 407 |
| IV. Petitions.....   | 410 |
| A. Citizen Petitions.....  | 411 |
| B. Petitions for Stay of Agency Actions.....   | 412 |
| C. 505(q) Petitions.....   | 412 |
| D. Frivolous Petitions .....   | 413 |
| 10. The Orange Book.....   | 417 |
| I. Overview of the Orange Book.....  | 418 |
| II. Patents Appropriate for Orange Book Listing .....                                | 420 |
| A. The Hatch-Waxman Act .....  | 420 |
| B. FDA Regulations .....   | 422 |
| 1. General Rules .....   | 422 |
| 2. Polymorph Patents .....   | 425 |
| 3. Product-by-Process Patents .....  | 426 |
| 4. Reissue Patents .....   | 426 |
| 5. Third-Party Patents .....   | 427 |
| 6. Patent Use Codes.....   | 429 |
| C. Implications of Orange Book Listings on Patent<br>Validity and Infringement ..... | 431 |
| 1. Anticipation .....  | 431 |
| 2. Marking.....  | 432 |
| III. The Timing of Patent Submissions .....  | 433 |
| IV. Orange Book Listing Disputes .....   | 435 |
| A. The Role of the FDA .....   | 435 |
| B. Delisting Litigation Prior to the MMA.....  | 436 |
| 1. Efforts by Generic Firms to Delist.....   | 437 |
| 2. Delisting by Brand-Name Firms .....   | 441 |
| C. Delisting Litigation Under the MMA.....   | 444 |
| 1. Efforts by Generic Firms to Delist.....   | 444 |
| 2. Delisting by Brand-Name Firms .....   | 448 |
| D. FTC Enforcement .....   | 450 |
| 11. Regulatory Exclusivities .....   | 453 |
| I. Regulatory Exclusivity Concepts.....  | 454 |
| II. New Chemical Entity Exclusivity .....  | 457 |
| A. Basic Concepts.....   | 457 |
| B. Combination Therapies.....  | 460 |
| III. New Clinical Study Exclusivity.....   | 461 |
| IV. Generic Exclusivity .....  | 465 |
| A. Basic Concepts.....   | 465 |
| B. Pre-MMA Standards .....   | 467 |
| 1. Entitlement.....  | 467 |
| 2. Timing of Notice .....  | 474 |
| 3. Commencement of the 180-Day Period .....  | 474 |
| 4. Separate Exclusivities for Distinct Dosages and<br>Strengths .....                | 476 |
| 5. Patent-by-Patent Approach.....  | 477 |



|   |     |
|---|-----|
| 6. Relationship to Pediatric Exclusivity .....                    | 478 |
| 7. Transferability .....  | 479 |
| C. Standards Under the MMA .....                                  | 479 |
| 1. Entitlement .....  | 479 |
| 2. Forfeiture .....   | 480 |
| 3. Timing of Notice .....   | 485 |
| 4. Commencement of the 180-Day Period .....                       | 485 |
| 5. Product-by-Product Approach .....                              | 486 |
| D. Unresolved Issues .....  | 486 |
| 1. Authorized Generics .....                                      | 486 |
| 2. Award of Exclusivity for Judgments of<br>Noninfringement ..... | 492 |
| V. Pediatric Exclusivity .....                                    | 492 |
| VI. Orphan Drug Exclusivity .....                                 | 495 |
| VII. Enantiomer Exclusivity .....                                 | 497 |
| VIII. Antibiotics Exclusivity .....                               | 498 |
| IX. Biologics Exclusivity .....                                   | 500 |
| X. Infectious Disease Product Exclusivity .....                   | 501 |
| XI. Transitional Exclusivity .....                                | 502 |

#### IV. Infringement

|   |     |
|---|-----|
| 12. Scope of Patent Rights .....  | 505 |
| I. Basic Concepts .....   | 506 |
| A. Direct Infringement .....  | 506 |
| B. Indirect Infringement .....  | 508 |
| 1. Active Inducement .....  | 509 |
| 2. Contributory Infringement .....  | 519 |
| 3. <i>Deepsouth</i> and 35 U.S.C. §271(f) .....                             | 521 |
| 4. Bioconversion as Infringement .....                                      | 522 |
| C. Process Patents .....  | 523 |
| 1. The Process Patent Amendments Act .....                                  | 523 |
| 2. Screening Methods .....  | 526 |
| D. Government Infringers .....  | 528 |
| 1. The Federal Government .....   | 529 |
| 2. The Bayh-Dole Act .....  | 532 |
| 3. State and Local Governments .....  | 534 |
| II. Infringement Under the Hatch-Waxman Act .....                           | 536 |
| A. Patent Implications of ANDAs and<br>Section 505(b)(2) Applications ..... | 537 |
| B. Notification of a Paragraph IV Certification .....                       | 543 |
| C. Offers of Confidential Access .....                                      | 544 |
| D. Infringement Analysis .....  | 544 |
| E. Generic Submissions for Unapproved Uses .....                            | 548 |
| III. Patent Litigation .....  | 550 |
| A. Subject Matter Jurisdiction .....  | 550 |
| B. Supplemental Jurisdiction .....  | 552 |

|   |     |
|---|-----|
| C. Personal Jurisdiction.....   | 553 |
| 1. General Principles.....  | 553 |
| 2. Implications of the Hatch-Waxman Act .....                             | 554 |
| D. Venue.....   | 555 |
| E. Declaratory Judgment.....  | 556 |
| 1. General Principles.....  | 556 |
| 2. Declaratory Judgment Actions in the<br>Hatch-Waxman Framework.....     | 560 |
| F. The Availability of Jury Trials Under the<br>Hatch-Waxman Act .....    | 570 |
| IV. Infringement Defenses.....  | 572 |
| A. Invalidity and Unenforceability .....                                  | 572 |
| B. Issue Preclusion.....  | 573 |
| C. Laches and Estoppel .....  | 574 |
| D. Licenses.....  | 576 |
| 1. Basic Concepts.....  | 576 |
| 2. Licensee and Assignor Estoppel .....                                   | 578 |
| 3. Implied Licenses.....  | 581 |
| 4. Shop Rights.....   | 583 |
| E. Prior User Rights .....  | 585 |
| V. Remedies.....  | 587 |
| A. General Principles.....  | 587 |
| 1. Injunctions .....  | 587 |
| 2. Compensatory Damages.....  | 592 |
| a. Reasonable Royalties.....  | 593 |
| b. Lost Profits.....  | 595 |
| i. “But For” Causation.....   | 595 |
| ii. Proximate Causation .....   | 599 |
| iii. The Entire Market Value Rule.....                                    | 600 |
| 3. Marking.....   | 601 |
| 4. Provisional Rights .....   | 603 |
| 5. Enhanced Damages .....   | 604 |
| B. Remedies Under the Hatch-Waxman Act .....                              | 607 |
| 1. Remedies Available for Infringing Generic<br>Applications .....        | 607 |
| 2. Generic Filings as Willful Infringements.....                          | 608 |
| C. Implications of Generic Market Entry During<br>Patent Litigation ..... | 610 |
| 13. Claim Interpretation and the Doctrine of Equivalents.....             | 615 |
| I. Claim Interpretation.....  | 616 |
| A. Basic Concepts.....  | 616 |
| B. <i>Markman v. Westview Instruments</i> .....                           | 617 |
| C. <i>Teva v. Sandoz</i> .....  | 619 |
| D. Canons of Claim Construction.....                                      | 621 |
| E. Dictionaries, the Specification, and the <i>Phillips</i><br>Case.....  | 625 |
| F. Representative Claim Construction Cases .....                          | 629 |

|   |     |
|---|-----|
| II. The Doctrine of Equivalents .....   | 640 |
| A. Basic Concepts.....  | 640 |
| 1. <i>Graver Tank</i> and the Function-Way-Result<br>Standard .....           | 641 |
| 2. <i>Warner-Jenkinson</i> and the Insubstantial<br>Differences Standard..... | 643 |
| 3. Vitiating .....  | 647 |
| 4. Functional Equivalents .....   | 648 |
| B. Limitations on the Doctrine of Equivalents.....                            | 649 |
| 1. The All Elements Rule .....  | 650 |
| 2. Prior Art Limitations.....   | 655 |
| 3. Prosecution History Estoppel .....   | 659 |
| 4. Disclosure-Dedication .....  | 668 |
| C. The Reverse Doctrine of Equivalents .....                                  | 674 |
| 14. Parallel Importation.....   | 677 |
| I. Introduction.....  | 677 |
| II. FDA Practices With Respect to Importing<br>Prescription Drugs .....       | 679 |
| A. The Prescription Drug Marketing Act of 1987 .....                          | 679 |
| B. The MEDS Act of 2000.....  | 681 |
| C. The MMA of 2003 .....  | 682 |
| D. Reform Proposals.....  | 683 |
| III. Patent Implications of Parallel Importation.....                         | 684 |
| A. The Exhaustion Doctrine .....  | 684 |
| B. International Exhaustion .....   | 685 |
| C. Reform Proposals.....  | 689 |
| D. Potential Legal Issues .....   | 689 |
| 1. The Takings Clause .....   | 689 |
| 2. State and Local Governments.....   | 695 |
| 3. The TRIPS Agreement .....  | 697 |
| 4. Free Trade Agreements.....   | 698 |
| 5. Label Licenses .....   | 700 |
| 15. The Experimental Use Privilege .....                                      | 703 |
| I. The Common Law Experimental Use Privilege .....                            | 706 |
| A. Origins of the Experimental Use Privilege .....                            | 706 |
| B. Cases Upholding the Privilege .....  | 708 |
| C. Experimental Use as a Matter of Remedies .....                             | 710 |
| D. Cases Rejecting the Experimental Use Privilege .....                       | 712 |
| E. The Common Law Experimental Use Privilege in<br>Pharmaceutical Cases.....  | 718 |
| F. The Common Law Experimental Use Privilege in<br>Academic Settings .....    | 719 |
| G. Experimental Use Policy.....   | 724 |
| II. The Statutory Experimental Use Privilege .....                            | 728 |
| A. Introduction to 35 U.S.C. §271(e)(1) .....                                 | 728 |
| 1. <i>Roche v. Bolar</i> .....  | 729 |

|  |     |
|--|-----|
| 2. The Hatch-Waxman Act .....                      | 731 |
| 3. Basic Analytical Framework.....                 | 732 |
| B. Application of 35 U.S.C. §271(e)(1) .....       | 738 |
| 1. Manufacture .....                               | 738 |
| 2. Preclinical Trials .....                        | 739 |
| 3. Clinical Trials .....                           | 743 |
| 4. Other Product Testing .....                     | 744 |
| 5. Sales .....                                     | 744 |
| 6. Displays and Demonstrations.....                | 745 |
| 7. Publications and Promotions .....               | 746 |
| 8. Foreign Patenting and Regulatory Approval ..... | 747 |
| 9. Medical Devices .....                           | 748 |
| 10. Research Tools .....                           | 754 |
| 11. Importation .....                              | 756 |
| 12. Post-Marketing Activity .....                  | 757 |
| 16. Antitrust Considerations .....                 | 763 |
| I. Introduction.....                               | 763 |
| II. Reverse Payment Settlements.....               | 764 |
| A. Notice of Patent Settlements .....              | 766 |
| B. <i>FTC v. Actavis</i> .....                     | 767 |
| C. Post- <i>Actavis</i> Developments .....         | 771 |
| 1. Applicability to Non-Cash Consideration .....   | 771 |
| 2. The Rule of Reason Analysis.....                | 773 |
| III. Product Hopping .....                         | 774 |

## V. International and Comparative Aspects

|  |     |
|--|-----|
| 17. International and Comparative Patent Law .....           | 781 |
| I. The Paris Convention.....                                 | 783 |
| A. National Treatment.....                                   | 783 |
| B. Independence of Patents .....                             | 783 |
| C. International Priority.....                               | 784 |
| D. Benefits of Paris Convention Priority .....               | 786 |
| E. Limitations of the Paris Convention .....                 | 786 |
| II. The Patent Cooperation Treaty .....                      | 787 |
| III. Foreign Filing Licenses .....                           | 789 |
| IV. Regional Agreements .....                                | 790 |
| A. NAFTA .....   | 790 |
| B. Other Regional Agreements.....                            | 791 |
| V. The TRIPS Agreement .....                                 | 792 |
| A. National Treatment and Most-Favored-Nation<br>Status..... | 792 |
| B. Minimum Standards of Protection .....                     | 793 |
| C. Compulsory Licenses.....                                  | 794 |
| 1. TRIPS Agreement Article 31.....                           | 794 |
| 2. The Doha Declaration .....                                | 796 |

|   |     |
|---|-----|
| D. Other Provisions.....                                    | 798 |
| E. Effective Dates.....                                     | 799 |
| 1. Pipeline Protection .....                                | 800 |
| 2. Exclusive Marketing Rights .....                         | 801 |
| F. Dispute Settlement .....                                 | 801 |
| 1. India Pharmaceutical Products .....                      | 802 |
| 2. Canada Pharmaceutical Products .....                     | 804 |
| G. Debate on the TRIPS Agreement .....                      | 806 |
| VI. Free Trade Agreements.....                              | 807 |
| A. Patent Term Restoration.....                             | 807 |
| B. Regulatory Exclusivity.....                              | 807 |
| C. Confidential Status of Experimental Data .....           | 808 |
| D. Accelerated Generic Marketing Approval.....              | 808 |
| E. Experimental Use Privilege.....                          | 809 |
| F. Parallel Importation.....                                | 809 |
| G. Implications .....                                       | 810 |
| VII. Comparative Patent Law .....                           | 810 |
| A. Deferred Examination.....                                | 811 |
| B. Experimental Use Privilege.....                          | 811 |
| C. Grace Period .....                                       | 813 |
| D. Methods of Medical Treatment.....                        | 813 |
| E. Patent Validity as an Infringement Defense.....          | 814 |
| F. Publication of Pending Applications.....                 | 814 |
| G. Patentable Subject Matter .....                          | 815 |
| H. The Promise of the Patent Doctrine .....                 | 816 |
| 18. International and Comparative Data Protection Law ..... | 819 |
| I. International Data Protection Standards.....             | 821 |
| A. The TRIPS Agreement .....                                | 821 |
| 1. Basic Principles .....                                   | 821 |
| 2. Eligible Data .....                                      | 822 |
| 3. Protection Against Unfair Commercial Use.....            | 824 |
| 4. Protection Against Disclosure.....                       | 827 |
| B. Free Trade Agreements.....                               | 828 |
| II. Comparative Law .....                                   | 829 |
| A. European Data Protection Law .....                       | 830 |
| 1. Introduction .....                                       | 830 |
| 2. Orphan Drugs.....  | 831 |
| 3. The Pediatric Testing Incentive.....                     | 832 |
| B. European Supplementary Protection Certificates.....      | 832 |
| C. Japan.....   | 835 |

## VI. Biologics

|                                  |     |
|----------------------------------|-----|
| 19. Follow-On Biologics.....     | 839 |
| I. Introduction.....             | 839 |
| II. The Regulatory Pathway ..... | 842 |

|   |         |
|---|---------|
| A. Biosimilars.....                                 | 842     |
| B. Interchangeable Biologics.....                   | 843     |
| C. The Role of the FDA.....                         | 844     |
| D. The Purple Book.....                             | 845     |
| III. Regulatory Exclusivities.....                  | 845     |
| A. Brand-Name Products.....                         | 846     |
| B. First Interchangeable Products.....              | 847     |
| IV. Patent Dispute Resolution.....                  | 848     |
| V. Current Issues.....                              | 852     |
| A. The “Patent Dance”: Optional or Mandatory? ..... | 852     |
| B. Retroactivity of the BPCIA.....                  | 854     |
| C. The President’s Annual Budget.....               | 855     |
| D. The Trans-Pacific Partnership.....               | 855     |
| V. Observations and Potential Issues.....           | 856     |
| <br>Table of Cases.....                             | <br>859 |
| Index .....   | 889     |
| About the Author .....                              | 907     |